ARTNA vs GNE

ARTNA's Piotroski F-Score of 4 indicates a weak financial health profile, signaling potential operational inefficiencies despite stable profitability. The absence of an Altman Z-Score raises concern about default risk, particularly given a current ratio of 0.68 and quick ratio of 0.40, which suggest liquidity strain. While the company trades at a reasonable P/E of 15.01 and offers a 3.8% dividend yield with a 55.85% payout ratio, its growth metrics lag behind sector peers. The stock is currently trading above its Graham Number ($34.4) and intrinsic value estimate ($22.78), indicating a premium valuation that may not be justified by fundamentals.

GNE exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9 and negligible debt (D/E 0.05), yet it is fundamentally overvalued. The current price of $13.79 significantly exceeds both the Graham Number ($6.99) and the growth-based Intrinsic Value ($2.03). While revenue growth remains robust at 23.6%, a sharp decline in earnings (-32% YoY) and a payout ratio exceeding 100% indicate an unsustainable dividend and deteriorating profitability. The combination of bearish technicals, insider selling, and consistent earnings misses suggests a high risk of price correction.